For a long time, eosinophils were regarded as the central effector cells of asthma and were interpreted in the classical model as a direct damaging agent of the epithelium, as an amplifier of bronchial hyperresponsiveness and as the main driver of type 2-mediated airway inflammation. Scientific developments over the past two decades have differentiated, expanded and in some cases questioned this picture. Are eosinophils in fact primary culprits – or merely markers of more complex immunological patterns? A new Lancet publication sheds some light on this.
Autoren
- Tanja Schliebe
Publikation
- Asthma/COPD-Special
Related Topics
You May Also Like
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Global Recommendation, Swissmedic Approval, and SL Limitation
WHO Guidelines on GLP-1 for Obesity
- Obesity in Children and Adolescents
Gene-Environment Interactions: Polygenic or Monogenic Determinants?
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- H. pylori infection: current study data
Fewer gastric carcinomas and peptic ulcers after eradication
- From symptom to diagnosis
Pneumology – tracheal and bronchial calcifications
- Tinea capitis: Current Guidelines and Recommendations
What should be kept in mind when treating adult patients?
- Geriatric patients